Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that it will issue financial results for its fiscal year ended September 30, 2022 on Monday November 28, 2022.
Related news for (AVXL)
- 24/7 Market News Snapshot 09 September, 2025 – Anavex Life Sciences (NASDAQ:AVXL)
- Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
- MoBot’s Stock Market Highlights – 07/23/25 02:00 PM
- Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
- Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update